DelveInsight’s latest analysis of the “Systemic Lupus Erythematosus Pipeline Insights 2025” delivers extensive intelligence on more than 120 organizations and over 140 developmental compounds in the Systemic Lupus Erythematosus therapeutic landscape. The analysis encompasses drug candidate profiles across both clinical and preclinical development phases. Additionally, it includes evaluation of Systemic Lupus Erythematosus investigational treatments by formulation type, developmental phase, administration method, and molecular classification. The report also identifies dormant pipeline candidates in this therapeutic area.
Obtain DelveInsight’s detailed Systemic Lupus Erythematosus Pipeline Analysis to discover novel treatments, major stakeholders, and upcoming therapeutic directions @ Systemic Lupus Erythematosus Pipeline Outlook Report
Essential Highlights from the Systemic Lupus Erythematosus Pipeline Analysis
- On October 28, 2025, Bristol-Myers Squibb initiated research to assess the efficacy and tolerability of deucravacitinib versus placebo in patients with active moderate to severe Systemic Lupus Erythematosus (SLE).
- On October 23, 2025, Sanofi launched a Phase 2, double-masked, 2-arm investigation assessing the therapeutic benefit and safety profile of SAR441344 versus placebo for treating patients aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE).
- On October 23, 2025, GlaxoSmithKline commenced research to assess the pharmacokinetic (PK) profile, safety parameters, and pharmacodynamic (PD) effects of repeated dosing of 200 milligrams per milliliter (mg/mL) belimumab delivered through subcutaneous (SC) injection in pediatric subjects aged 5 to 17 years with SLE receiving standard care therapy. This bridging PK investigation forms part of an extrapolation approach to support SC belimumab use in pediatric SLE patients, building upon the completed adult SLE trial with SC belimumab and the pediatric SLE investigation with intravenous (IV) belimumab.
- On October 23, 2025, AstraZeneca established a Phase 3 investigation to determine the therapeutic effectiveness and safety of a subcutaneous dosing protocol of anifrolumab compared to placebo in subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care (SOC) treatment. Subjects must be receiving either one or any combination of: oral corticosteroids, antimalarial agents, and/or immunosuppressive medications. The investigation will enroll adult subjects aged 18 to 70 years.
- DelveInsight’s Systemic Lupus Erythematosus pipeline analysis reveals a dynamic field with over 120 active organizations advancing more than 140 pipeline candidates for Systemic Lupus Erythematosus therapy.
- The prominent Systemic Lupus Erythematosus Companies include Biogen, Idorsia Pharmaceuticals, AbbVie, Biosenic, Roche, Eisai, Daiichi Sankyo Company, Carna Bioscience, Asahi Kasei Pharma, Sanofi, Alpine Immune Sciences, Novartis Pharmaceuticals, Sana Biotechnology and additional organizations.
- Notable Systemic Lupus Erythematosus Pipeline Therapies include Obexelimab, Telitacicept, DS-7011a, Belimumab, Sirolimus, Ianalumab, Belimumab (GSK1550188), BMS-986165, JMKX000189, and additional candidates.
Access DelveInsight’s comprehensive Systemic Lupus Erythematosus Pipeline Evaluation for an in-depth examination of promising advances @ Systemic Lupus Erythematosus Clinical Trials and Studies
Systemic Lupus Erythematosus Background
Systemic Lupus Erythematosus (SLE) represents a chronic autoimmune condition distinguished by inflammation and tissue injury affecting multiple organ systems, including skin, joints, kidneys, cardiovascular system, and respiratory system. SLE occurs when the immune system attacks the body’s own healthy tissues due to failure in distinguishing between self-cells and external pathogens. This mechanism produces widespread inflammation and can result in substantial morbidity, establishing SLE as a highly heterogeneous and intricate disease to diagnose, manage, and treat. The disorder predominantly impacts women, especially during reproductive years, and demonstrates higher prevalence in specific ethnic populations, including African Americans, Hispanics, and Asians, suggesting that both hormonal influences and genetic elements may contribute to disease predisposition.
Systemic Lupus Erythematosus Emerging Drug Profiles
BIIB059: Biogen
BIIB059, alternatively designated as Litifilimab, represents a humanized IgG1 monoclonal antibody created by Biogen, directed against blood dendritic cell antigen 2 (BDCA2). This antibody is chiefly investigated for therapeutic applications in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), both representing chronic autoimmune disorders. BIIB059 selectively binds to BDCA2, a receptor expressed exclusively on plasmacytoid dendritic cells (pDCs). Through binding to this receptor, BIIB059 suppresses the generation of type-I interferon (IFN-I) and additional pro-inflammatory cytokines, which play roles in lupus pathogenesis. This mechanism holds significance as pDCs are recognized for generating substantial quantities of IFN-I following immune activation, contributing to inflammatory cascades observed in lupus patients. Presently, the compound is advancing through Phase III clinical investigation for Systemic Lupus Erythematosus treatment.
Cenerimod: Idorsia Pharmaceuticals
Cenerimod, created by Idorsia Pharmaceuticals, represents a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator undergoing investigation primarily for systemic lupus erythematosus (SLE) treatment. This innovative oral medication seeks to address unmet therapeutic needs in SLE, a chronic autoimmune disorder characterized by considerable morbidity and restricted treatment alternatives. Presently, the compound is advancing through Phase III clinical investigation for Systemic Lupus Erythematosus treatment.
ABBV 599: AbbVie
ABBV-599, created by AbbVie, represents an innovative fixed-dose combination treatment that merges two established agents: elsubrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, and upadacitinib, a Janus kinase (JAK) inhibitor. This combination is chiefly undergoing investigation for autoimmune disease treatment, particularly systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Presently, the compound is in Phase II development for Systemic Lupus Erythematosus treatment.
Arscimed: Biosenic
Arscimed, created by BioSenic, represents an innovative compound utilizing arsenic trioxide to address autoimmune diseases at the origin of the immune cascade. This treatment is specifically concentrated on conditions including chronic graft-versus-host disease (cGVHD), systemic lupus erythematosus (SLE), and systemic sclerosis. Presently, the compound is in Phase II development for Systemic Lupus Erythematosus treatment.
Mosunetuzumab: Roche
Mosunetuzumab, a bispecific antibody created by Roche, is currently undergoing evaluation for potential application in treating systemic lupus erythematosus (SLE), a chronic autoimmune disorder. This investigational treatment targets both CD20 on B cells and CD3 on T cells, designed to enhance immune activity against autoantibody-generating B cells. Presently, the compound is in Phase I development for Systemic Lupus Erythematosus treatment.
The Systemic Lupus Erythematosus Pipeline Report Delivers Intelligence Into
- The analysis delivers comprehensive intelligence about organizations developing treatments for Systemic Lupus Erythematosus with aggregated therapies developed by each organization for the same indication.
- It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Systemic Lupus Erythematosus Treatment.
- Systemic Lupus Erythematosus Companies are engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) projects.
- Systemic Lupus Erythematosus Drugs in development classified by developmental phase, administration route, target receptor, monotherapy or combination therapy, various mechanisms of action, and molecular classification.
- Comprehensive analysis of partnerships (company-company partnerships and company-academia partnerships), licensing agreements and financial arrangements for future progression of the Systemic Lupus Erythematosus market
Discover groundbreaking treatments and clinical investigations in the Systemic Lupus Erythematosus Pipeline. Access DelveInsight’s comprehensive analysis now! @ New Systemic Lupus Erythematosus Drugs
Systemic Lupus Erythematosus Companies
Biogen, Idorsia Pharmaceuticals, AbbVie, Biosenic, Roche, Eisai, Daiichi Sankyo Company, Carna Bioscience, Asahi Kasei Pharma, Sanofi, Alpine Immune Sciences, Novartis Pharmaceuticals, Sana Biotechnology and additional organizations.
Systemic Lupus Erythematosus Pipeline Analysis Delivers Therapeutic Evaluation
The pipeline analysis delivers therapeutic evaluation of developmental drugs by Administration Route. Products have been organized under various administration routes including:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Systemic Lupus Erythematosus Products Organized by Molecular Classification
Products have been organized under various molecular types including:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download DelveInsight’s current analysis to obtain strategic intelligence into emerging treatments and significant developments @ Systemic Lupus Erythematosus Market Drivers and Barriers, and Future Perspectives
Parameters of the Systemic Lupus Erythematosus Pipeline Analysis
- Coverage- Global
- Systemic Lupus Erythematosus Companies- Biogen, Idorsia Pharmaceuticals, AbbVie, Biosenic, Roche, Eisai, Daiichi Sankyo Company, Carna Bioscience, Asahi Kasei Pharma, Sanofi, Alpine Immune Sciences, Novartis Pharmaceuticals, Sana Biotechnology and additional organizations.
- Systemic Lupus Erythematosus Pipeline Therapies- Obexelimab, Telitacicept, DS-7011a, Belimumab, Sirolimus, Ianalumab, Belimumab (GSK1550188), BMS-986165, JMKX000189, and additional candidates.
- Systemic Lupus Erythematosus Therapeutic Evaluation by Product Type: Mono, Combination, Mono/Combination
- Systemic Lupus Erythematosus Therapeutic Evaluation by Clinical Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discover details in DelveInsight’s exclusive Systemic Lupus Erythematosus Pipeline Analysis—access it now! @ Systemic Lupus Erythematosus Emerging Drugs and Major Companies
Contents Overview
* Introduction
* Executive Summary
* Systemic Lupus Erythematosus: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Systemic Lupus Erythematosus – DelveInsight’s Analytical Perspective
* Late Stage Products (Phase III)
* BIIB059: Biogen
* Drug profiles in the detailed report…..
* Mid Stage Products (Phase II)
* ABBV 599: AbbVie
* Drug profiles in the detailed report…..
* Early Stage Products (Phase I)
* Mosunetuzumab: Roche
* Drug profiles in the detailed report…..
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report…..
* Inactive Products
* Systemic Lupus Erythematosus – Collaborations Assessment- Licensing / Partnering / Funding
* Systemic Lupus Erythematosus – Unmet Needs
* Systemic Lupus Erythematosus – Market Drivers and Barriers
* Appendix
About Us
DelveInsight operates as a premier healthcare-focused market research and consulting organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and profound expertise in the life sciences and healthcare domains, we provide tailored research solutions and intelligence to clients worldwide. Connect with us to obtain high-quality, precise, and real-time intelligence to maintain competitive advantage in the growth trajectory.
Contact Us
Kanishk
kkumar@delveinsight.com